Anavex Life Sciences Corp (AVXL)

[Gator328]

I agree that in the end the only thing that matters is safety and efficacy in properly conducted human trials.

But it seems to me that many failed drug candidates initially had mice or rodent trials that went well enough to justify further trials. This is why I have a difficult time becoming too excited over A371. It looks promising, but the murine tests are so preliminary that it's nearly impossible to say that they mean anything other than further investigation is needed.

I'd much prefer a successful murine trial than a failed one. But as you may or may not recall, many investors were ecstatic about Anavex's P2A trial in July 2015. According to them, approval was two or three years away. We're now going on 7+.

A371 may be the future but for now, my hope is that Blarcamesine gets approved because without recurring revenue, there may not be enough of a runway to finance the A371 tests through to completion without significant dilution to existing shareholders.